BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23490373)

  • 1. IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication.
    Shindo H; Maekawa S; Komase K; Miura M; Kadokura M; Sueki R; Komatsu N; Shindo K; Amemiya F; Nakayama Y; Inoue T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Viral Hepat; 2013 Apr; 20(4):281-9. PubMed ID: 23490373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1.
    Cheng M; Si Y; Niu Y; Liu X; Li X; Zhao J; Jin Q; Yang W
    J Virol; 2013 Sep; 87(17):9707-18. PubMed ID: 23824794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
    Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
    Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
    Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
    PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
    Liu B; Chen S; Guan Y; Chen L
    PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
    Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
    J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
    Zhu H; Butera M; Nelson DR; Liu C
    Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
    Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
    Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.
    Yoshio S; Kanto T; Kuroda S; Matsubara T; Higashitani K; Kakita N; Ishida H; Hiramatsu N; Nagano H; Sugiyama M; Murata K; Fukuhara T; Matsuura Y; Hayashi N; Mizokami M; Takehara T
    Hepatology; 2013 May; 57(5):1705-15. PubMed ID: 23213063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection.
    Meng X; Yang D; Yu R; Zhu H
    Mediators Inflamm; 2015; 2015():716315. PubMed ID: 26146465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response.
    Bauhofer O; Ruggieri A; Schmid B; Schirmacher P; Bartenschlager R
    Gastroenterology; 2012 Aug; 143(2):429-38.e8. PubMed ID: 22522091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
    Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
    Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
    Erickson AK; Seiwert S; Gale M
    Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness.
    Cheng M; Si Y; Yang Y; Liu X; Gong Q; Zhao J; Niu Y; Li X; Jin Q; Yang W
    J Antimicrob Chemother; 2012 May; 67(5):1080-7. PubMed ID: 22323501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro.
    Kuga C; Enomoto H; Aizawa N; Takashima T; Ikeda N; Ishii A; Sakai Y; Iwata Y; Tanaka H; Saito M; Iijma H; Nishiguchi S
    Biochem Biophys Res Commun; 2014 Nov; 454(3):453-8. PubMed ID: 25450683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.